mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2021-2-69-76mrj-1125Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSАваскулярный некроз при системной красной волчанке: тотальное эндопротезирование тазобедренного сустава при мутации в гене V (Leiden) фактора свертывания крови (клиническое наблюдение)Avascular necrosis in systemic lupus erythematosus: total hip replacement in a patient with mutation in clotting factor V (Leiden) gene, clinical observationhttps://orcid.org/0000-0001-5217-4932ЧельдиеваФ. А.CheldievaF. A.

Кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России

115522, Москва, Каширское шоссе, 34А,

125993, Москва, ул. Баррикадная, 2/1, стр. 1

Department of rheumatology, Russian Medical Academy of Continuing Professional Education

34A, Kashirskoe Shosse, Moscow 115522,

2/1, Barrikadnaya St., Build. 1, Moscow 125993

https://orcid.org/0000-0002-3470-9726КушнареваИ. Г.KushnarevaI. G.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0001-8020-2494БабакВ. В.BabakV. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0002-2198-1229ХрамовА. Э.KhramovA. E.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

https://orcid.org/0000-0003-3552-2522РешетнякТ. М.ReshetnyakT. M.

Татьяна Магомедалиевна Решетняк

Кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России

115522, Москва, Каширское шоссе, 34А,

125993, Москва, ул. Баррикадная, 2/1, стр. 1

Tatiana Magomedalievna Reshetnyak

Department of rheumatology, Russian Medical Academy of Continuing Professional Education

34A, Kashirskoe Shosse, Moscow 115522,

2/1, Barrikadnaya St., Build. 1, Moscow 125993

t_reshetnyak@yahoo.comФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional EducationRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation2021230420211526976Copyright © Чельдиева Ф.А., Кушнарева И.Г., Бабак В.В., Храмов А.Э., Решетняк Т.М., 20212021Чельдиева Ф.А., Кушнарева И.Г., Бабак В.В., Храмов А.Э., Решетняк Т.М.Cheldieva F.A., Kushnareva I.G., Babak V.V., Khramov A.E., Reshetnyak T.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1125

В статье приводится описание пациентки с системной красной волчанкой, множественными аваскулярными некрозами костей (АВН), гомозиготной мутацией в гене V фактора свертывания крови, успешно перенесшей тотальное эндопротезирование тазобедренного сустава. Обсуждается роль в развитии АВН высоких доз глюкокортикоидов и нарушений свертывания крови, в частности гомозиготной мутации Leiden.

The article provides a description of the systemic lupus erythematosus patient with multiple avascular bone necrosis (ABN), homozygous mutation in clotting factor V (Leiden) gene, who successfully underwent the total hip replacement. The role of high doses of glucocorticoids and coagulation disorders, in particular the homozygous mutation in factor V (Leiden) gene, in the development of ABN is discussed.

системная красная волчанкааваскулярный некроз костеймутация Leidenглюкокортикоидыsystemic lupus erythematosusavascular bone necrosisLeiden mutationglucocorticoidsReferencesРешетняк ТМ, Лисицына ТА, Насонов ЕЛ. Остеонекрозы при системной красной волчанке и антифосфолипидном синдроме. Клиническая медицина. 2004;82(6):46-51.Reshetnyak TM, Lisitsyna TA, Nasonov EL. Osteonecrosis in systemic lupus erythematosus and antiphospholipid syndrome. Klinicheskaya meditsina. 2004;82(6):46-51. (In Russ.).Насонова ВА. Остеонекроз тазобедренного сустава. Consilium medicum. 2003;(2):90-5.Nasonova VA. Osteonecrosis of the hip joint. Consilium medicum. 2003;(2):90-5. (In Russ.).Hussein S, Suitner M, Beland-Bonenfant S, et al. Monitoring of Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review and Metaanalysis. J Rheumatol. 2018 Oct;45(10):1462-76. doi: 10.3899/jrheum.170837. Epub 2018 Jul 1.Hussein S, Suitner M, Beland-Bonenfant S, et al. Monitoring of Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review and Metaanalysis. J Rheumatol. 2018 Oct;45(10):1462-76. doi: 10.3899/jrheum.170837. Epub 2018 Jul 1.Nevskaya T, Gamble MP, Pope JE. A metaanalysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors. Clin Exp Rheumatol. Jul-Aug 2017;35(4): 700-10. Epub 2017 Feb 24.Nevskaya T, Gamble MP, Pope JE. A metaanalysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors. Clin Exp Rheumatol. Jul-Aug 2017;35(4): 700-10. Epub 2017 Feb 24.Gurion R, Tangpricha V, Yow E, et al. Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature. Pediatr Rheumatol Online J. 2015 Apr 23;13:13. doi: 10.1186/s12969-015-0008-x.Gurion R, Tangpricha V, Yow E, et al. Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature. Pediatr Rheumatol Online J. 2015 Apr 23;13:13. doi: 10.1186/s12969-015-0008-x.Gladman DD, Dhillon N, Su J, Urowitz MB. Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors. Lupus. 2018 Jan; 27(1):76-81. doi: 10.1177/0961203317711012. Epub 2017 May 22.Gladman DD, Dhillon N, Su J, Urowitz MB. Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors. Lupus. 2018 Jan; 27(1):76-81. doi: 10.1177/0961203317711012. Epub 2017 May 22.Prasad R, Ibanez D, Gladman D, Urowitz M. The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients. Lupus. 2007;16(3):157-62. doi: 10.1177/0961203306075771.Prasad R, Ibanez D, Gladman D, Urowitz M. The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients. Lupus. 2007;16(3):157-62. doi: 10.1177/0961203306075771.Gladman DD, Chaudhry-Ahluwalia V, Ibanez D, et al. Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol. 2001 Oct;28(10):2226-9.Gladman DD, Chaudhry-Ahluwalia V, Ibanez D, et al. Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol. 2001 Oct;28(10):2226-9.Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 Mar;39(3):363-9. doi: 10.1002/art.1780390303.Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 Mar;39(3):363-9. doi: 10.1002/art.1780390303.Kwon HH, Bang SY, Won S, et al. Synergistic effect of cumulative corticosteroid dose and immunosuppressants on avascular necrosis in patients with systemic lupus erythematosus. Lupus. 2018 Sep;27(10):1644-51. doi: 10.1177/0961203318784648. Epub 2018 Jun 27.Kwon HH, Bang SY, Won S, et al. Synergistic effect of cumulative corticosteroid dose and immunosuppressants on avascular necrosis in patients with systemic lupus erythematosus. Lupus. 2018 Sep;27(10):1644-51. doi: 10.1177/0961203318784648. Epub 2018 Jun 27.Shah KN, Racine J, Jones LC, Aaron RK. Pathophysiology and risk factors for osteonecrosis. Curr Rev Musculoskelet Med. 2015 Sep; 8(3):201-9. doi: 10.1007/s12178-015-9277-8.Shah KN, Racine J, Jones LC, Aaron RK. Pathophysiology and risk factors for osteonecrosis. Curr Rev Musculoskelet Med. 2015 Sep; 8(3):201-9. doi: 10.1007/s12178-015-9277-8.Tsai SW, Wu PK. Etiologies and outcome of osteonecrosis of the femoral head: Etiology and outcome study in a Taiwan population. J Chin Med Assoc. 2016 Jan;79(1):39-45. doi: 10.1016/j.jcma.2015.07.010. Epub 2015 Sep 19.Tsai SW, Wu PK. Etiologies and outcome of osteonecrosis of the femoral head: Etiology and outcome study in a Taiwan population. J Chin Med Assoc. 2016 Jan;79(1):39-45. doi: 10.1016/j.jcma.2015.07.010. Epub 2015 Sep 19.Glueck CJ, Freiberg RA, Wang P. Heritable thrombophiliahypo fibrinolysis and osteonecrosis of the femoral head. Clin Orthop Relat Res. 2008 May;466(5):1034-40. doi: 10.1007/s11999-008-0148-0. Epub 2008 Mar 19.Glueck CJ, Freiberg RA, Wang P. Heritable thrombophiliahypo fibrinolysis and osteonecrosis of the femoral head. Clin Orthop Relat Res. 2008 May;466(5):1034-40. doi: 10.1007/s11999-008-0148-0. Epub 2008 Mar 19.Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002 Oct;32(2):94-124.Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002 Oct;32(2):94-124.Malizos KN, Karantanas AH, Varitimidis SE, et al. Osteonecrosis of the femoral head: etiology, imaging and treatment. Eur J Radiol. 2007 Jul;63(1):16-28. doi: 10.1016/j.ejrad.2007.03.019. Epub 2007 Jun 6.Malizos KN, Karantanas AH, Varitimidis SE, et al. Osteonecrosis of the femoral head: etiology, imaging and treatment. Eur J Radiol. 2007 Jul;63(1):16-28. doi: 10.1016/j.ejrad.2007.03.019. Epub 2007 Jun 6.Lafforgue P. Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine. 2006 Oct;73(5):500-7. doi: 10.1016/j.jbspin.2006.01.025. Epub 2006 Aug 8.Lafforgue P. Pathophysiology and natural history of avascular necrosis of bone. Joint Bone Spine. 2006 Oct;73(5):500-7. doi: 10.1016/j.jbspin.2006.01.025. Epub 2006 Aug 8.Glueck CJ, Glueck HI, Mieczkowski L, et al. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis? Thromb Haemost. 1993 May 3;69(5):460-5.Glueck CJ, Glueck HI, Mieczkowski L, et al. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis? Thromb Haemost. 1993 May 3;69(5):460-5.Glueck CJ, Freiberg R, Tracy T, et al. Thrombophilia and hypofibrinolysis: Pathophysiologies of osteonecrosis. Clin Orthop Relat Res. 1997 Jan;(334):43-56.Glueck CJ, Freiberg R, Tracy T, et al. Thrombophilia and hypofibrinolysis: Pathophysiologies of osteonecrosis. Clin Orthop Relat Res. 1997 Jan;(334):43-56.Glueck CJ, Freiberg RA, Fontaine RN, et al. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res. 2001 May;(386):19-33. doi: 10.1097/00003086-200105000-00004.Glueck CJ, Freiberg RA, Fontaine RN, et al. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res. 2001 May;(386):19-33. doi: 10.1097/00003086-200105000-00004.Bjorkman A, Svensson PJ, Hillarp A, et al. Factor V Leiden and prothrombin gene mutation: Risk factors for osteonecrosis of the femoral head in adults. Clin Orthop Relat Res. 2004 Aug;(425):168-72.Bjorkman A, Svensson PJ, Hillarp A, et al. Factor V Leiden and prothrombin gene mutation: Risk factors for osteonecrosis of the femoral head in adults. Clin Orthop Relat Res. 2004 Aug;(425):168-72.Salvati EA, Della Valle AG, Westrich GH, et al. The John Charnley Award: Heritable thrombophilia and development of thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res. 2005 Dec;441:40-55. doi: 10.1097/01.blo.0000192366.61616.81.Salvati EA, Della Valle AG, Westrich GH, et al. The John Charnley Award: Heritable thrombophilia and development of thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res. 2005 Dec;441:40-55. doi: 10.1097/01.blo.0000192366.61616.81.Merayo-Chalico J, Gonzalez-Contreras M, Ortiz-Hernandez R, et al. Total hip arthroplasty outcomes: an 18-year experience in a single center: is systemic lupus erythematosus a potential risk factor for adverse outcomes? J Arthroplasty. 2017 Nov;32(11):3462-67. doi: 10.1016/j.arth.2017.06.021. Epub 2017 Jun 19.Merayo-Chalico J, Gonzalez-Contreras M, Ortiz-Hernandez R, et al. Total hip arthroplasty outcomes: an 18-year experience in a single center: is systemic lupus erythematosus a potential risk factor for adverse outcomes? J Arthroplasty. 2017 Nov;32(11):3462-67. doi: 10.1016/j.arth.2017.06.021. Epub 2017 Jun 19.Kasturi S, Goodman S. Current perspectives on arthroplasty in systemic lupus erythematosus: rates, outcomes, and adverse events. Curr Rheumatol Rep. 2016 Sep;18(9):59. doi: 10.1007/s11926-016-0608-6.Kasturi S, Goodman S. Current perspectives on arthroplasty in systemic lupus erythematosus: rates, outcomes, and adverse events. Curr Rheumatol Rep. 2016 Sep;18(9):59. doi: 10.1007/s11926-016-0608-6.Schnaser EA, Browne JA, Padgett DE, et al. Perioperative complications in patients with inflammatory arthropathy undergoing Total hip arthroplasty. J Arthroplasty. 2016 Oct; 31(10):2286-90. doi: 10.1016/j.arth.2016.03.023. Epub 2016 Mar 21.Schnaser EA, Browne JA, Padgett DE, et al. Perioperative complications in patients with inflammatory arthropathy undergoing Total hip arthroplasty. J Arthroplasty. 2016 Oct; 31(10):2286-90. doi: 10.1016/j.arth.2016.03.023. Epub 2016 Mar 21.Fein AW, Figgie CA, Dodds TR, et al. Systemic lupus erythematosus does not increase risk of adverse events in the first 6 months after Total knee arthroplasty. J Clin Rheumatol. 2016 Oct;22(7):355-9. doi: 10.1097/RHU.0000000000000435.Fein AW, Figgie CA, Dodds TR, et al. Systemic lupus erythematosus does not increase risk of adverse events in the first 6 months after Total knee arthroplasty. J Clin Rheumatol. 2016 Oct;22(7):355-9. doi: 10.1097/RHU.0000000000000435.Chen CH, Chen TH, Lin YS, et al. The impact of systemic lupus erythematosus on the risk of infection after total hip arthroplasty: a nationwide population-based matched cohort study. Arthritis Res Ther. 2020 Sep 14; 22(1):214. doi: 10.1186/s13075-020-02300-1.Chen CH, Chen TH, Lin YS, et al. The impact of systemic lupus erythematosus on the risk of infection after total hip arthroplasty: a nationwide population-based matched cohort study. Arthritis Res Ther. 2020 Sep 14; 22(1):214. doi: 10.1186/s13075-020-02300-1.

The authors declare that there are no conflicts of interest present.